EXEL Exelixis Inc

$42.51

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

None

Updated On 11/21/2025

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.

Website: https://www.exelixis.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
939767
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, US
Valuation
Market Cap
$9.97B
P/E Ratio
20.56
PEG Ratio
2.27
Price to Book
4.44
Performance
EPS
$1.76
Dividend Yield
—
Profit Margin
24.00%
ROE
23.10%
Technicals
50D MA
$36.30
200D MA
$31.23
52W High
$40.02
52W Low
$20.14
Fundamentals
Shares Outstanding
276M
Target Price
$37.95
Beta
0.57

EXEL EPS Estimates vs Actual

● Estimated
● Actual

EXEL News & Sentiment

Nov 17, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Why Exelixis ( EXEL ) International Revenue Trends Deserve Your Attention
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Nov 13, 2025 • Zacks Commentary NEUTRAL
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nov 12, 2025 • Zacks Commentary BULLISH
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nov 11, 2025 • Zacks Commentary BULLISH
Why Exelixis ( EXEL ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nov 06, 2025 • Zacks Commentary BULLISH
Company News for Nov 6, 2025
Companies In The News Are: AMGN, EXEL, LITE, MCD.
Nov 05, 2025 • Zacks Commentary NEUTRAL
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Sentiment Snapshot

Average Sentiment Score:

0.191
50 articles with scored sentiment

Overall Sentiment:

Bullish

EXEL Reported Earnings

Jul 28, 2025
Jun 30, 2025 (Pre market)
0.11 Surprise
  • Reported EPS: $0.75
  • Estimate: $0.64
  • Whisper: —
  • Surprise %: 17.2%
May 13, 2025
Mar 31, 2025 (Pre market)
0.25 Surprise
  • Reported EPS: $0.62
  • Estimate: $0.37
  • Whisper: —
  • Surprise %: 69.1%
Feb 11, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.49
  • Whisper: —
  • Surprise %: 11.8%
Oct 29, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 14.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.47 Surprise
  • Reported EPS: $0.77
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: 156.7%
Apr 30, 2024
Mar 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.20
  • Estimate: $0.24
  • Whisper: —
  • Surprise %: -16.7%
Feb 06, 2024
Dec 31, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $0.27
  • Estimate: $0.21
  • Whisper: —
  • Surprise %: 28.6%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.10
  • Estimate: $0.10
  • Whisper: —
  • Surprise %: 0.0%
Aug 01, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.25
  • Estimate: $0.16
  • Whisper: —
  • Surprise %: 56.2%

Financials